Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect and Safety of Semaglutide 2.4 mg Once Weekly on Weight Management in Adolescents With Overweight or Obesity

NCT04102189 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT04102189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04102189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect and Safety of Semaglutide 2.4 mg Once Weekly on Weight Management in Adolescents With Overweight or Obesity
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
October 7, 2019
Completion date
March 28, 2022
Enrollment
201 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight